INDEMNIFICATION AGREEMENTIndemnification Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [●], 2024 between Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 6, 2024, by and among Oruka Therapeutics, Inc. a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the securityholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”.
March 11, 2024 Arjun Agarwal Email – Re: Offer of Employment Dear Arjun:Offer of Employment • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
On behalf of Oruka Therapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Senior Vice President, Finance (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.
ORUKA THERAPEUTICS, INC.Ceo Offer Letter Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
On behalf of the Board of Directors of Oruka Therapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Executive Officer of the Company (“CEO”) and a member of the Company’s Board of Directors (the “Board”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. This Agreement amends and restates that certain letter agreement dated February 6, 2024.
ORUKA Therapeutics, Inc. AMENDED AND RESTATED Stock Option Agreement [Incentive stock option // non-statutory stock option]Stock Option Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
ORUKA THERAPEUTICS, INC. RESTRICTED STOCK NOTICERestricted Stock Purchase Agreement • May 14th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware
Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to Purchaser (as defined below) the number of Shares (as defined below) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) set forth below, upon the terms and subject to the conditions set forth in the Restricted Stock Purchase Agreement attached hereto as Exhibit A (the “Restricted Stock Purchase Agreement”), which is incorporated by reference in this Notice (as defined in the Restricted Stock Purchase Agreement). The issuance and sale of the Shares shall be effective as of the Date of Grant, set forth below.
